logo
  

Amgen : FDA Approves Kyprolis Combination Regimen For Multiple Myeloma Treatment

Amgen (AMGN) said that the U.S. Food and Drug Administration has approved the expansion of the Kyprolis or carfilzomib U.S. prescribing information to include its use in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

The approval is supported by the ongoing, phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of Darzalex Faspro administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma. The study met its primary endpoint, demonstrating an overall response rate of 84.8 percent with Darzalex Faspro-Kd.

Amgen noted that serious adverse reactions occurred in 27% of patients who received KYPROLIS in combination with DARZALEX FASPRO and dexamethasone. The most common adverse reactions (=20%) were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea and peripheral edema. Fatal adverse reactions occurred in 3% of patients.

Amgen said it will be submitting marketing applications globally.

Darzalex Faspro And Darzalex are registered trademarks of Johnson & Johnson.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Richmond, Utah-based Casper's Ice Cream is recalling its 56 ounce tubs of "Red Button Vintage Creamery Canadian Vanilla Ice Cream" due to undeclared allergen, the U.S. Food and Drug Administration said. According to the agency, a limited number of the product were mispackaged with Burnt Almond Fudge Ice Cream containing undeclared almonds. Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June.
Follow RTT